Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance Banks $100m As J&J Bets Big On IBD Drug

Executive Summary

If the JAK inhibitor codenamed TD-1473 proves effective in Crohn’s disease and ulcerative colitis, the clinical, regulatory and commercial know-how in IBD from partner Janssen could help Theravance pocket $1bn.

Advertisement

Related Content

Landos Leverages Advanced Computing For Autoimmune Disease Drug Development
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms
Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor
Galapagos Eyes Rare European Biotech Heavyweight Title, Launches $338m Offering

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel